Hiku Brands Company Ltd. (“Hiku”)(CSE:HIKU,OTCUS:DJACF), Canada’s first vertically-integrated cannabis brand house, is pleased to announce it has entered into a letter of intent to establish a co-marketing, retail and select distribution relationship with dosist (previously known as hmbldt), a leading wellness brand recognized as a disruptor in the health industry and named by Fast Company as one of the world’s 10 most innovative companies in the health sector in 2018.

Once dosist cannabis products become legally permitted to be sold for adult-use in Canada, consumers will be able to purchase dosist’s highly innovative targeted formulas at Hiku-owned licensed cannabis stores. In select areas, where permitted, Hiku-owned licensed cannabis stores will feature an immersive dosist experience where Hiku will be the exclusive retailer of dosist products.


“Hiku is focused on bringing Canadians truly exceptional products and experiences, and dosist fits perfectly into our growing family of brands and partners. Hiku and dosist are committed to helping Canadians understand the cannabis landscape and consume in a responsible manner,” says Alan Gertner, CEO of Hiku. “We’re excited to bring dosist’s amazing products to Canadians soon, and in the meantime, work with them to continue to educate, inform and normalize cannabis for consumers.”

dosist is dedicated to providing consistent, controlled and effective cannabis-based solutions through targeted formulations of the active ingredients found in cannabis. The company delivers precise dosage through its recyclable, proprietary, medical grade vaporizer, the dose pen™. dosist’s products are designed for clarity and control from their beautifully designed packaging to the slight vibration which alerts the user after they’ve received a precise 2.25mg dose. dosist’s targeted formulas and propriety dose pen were named one of TIME magazine’s best inventions of 2016.

“We’re thrilled to be working with Hiku. They’ve demonstrated a commitment to cannabis-related education, working to remove the stigma surrounding the plant,” said Josh Campbell, President of dosist. “We chose Hiku because of their vision for the future and their commitment to the best in class customer experience.”

About Hiku:
Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA‘s ACMPR licensed grow, and Van der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

About dosist™: 
Named one of Time Magazine’s Best Inventions of 2016, dosist™ is a cannabis-based wellness company. Through six targeted formulas, dosist aims to deliver safe, targeted and effective solutions for some of our most common ailments. The company takes an ethical approach to production, which includes fully recyclable, medical-grade plastic and a rigorous testing process to ensure all products are safe and pesticide-free. www.dosist.ca @dosist.ca

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this news release include statements regarding Hiku’s expectations regarding the availability of dosist’s targeted formulas and products in Hiku owned stores.  By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

For Hiku press inquiries or to book an interview, please contact:
Abigail Van Den Broek abby@abigailv.ca; 416-799-8510

For dosist™ press inquiries or to book an interview, please contact:
Lexi Pathak (Toronto) lexi@dosist.com; Faulhaber Communications, 416-504-0768 x 227
Malania Dela Cruz (Vancouver) malania@dosist.com; Faulhaber Communications, 778-379-6222

Click here to connect with Hiku Brands Company Ltd. and receive an Investor’s Presentation.

Source: globenewswire.com

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less